Protective efficacy of a recombinant herpesvirus of turkeys as an in ovo vaccine against Newcastle and Marek's diseases in specific-pathogen-free chickens

S. K. Reddy, J. M. Sharma, J. Ahmad, D. N. Reddy, J. K. McMillen, S. M. Cook, M. A. Wild, R. D. Schwartz

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

We investigated the potential of a herpesvirus of turkey (HVT)-based recombinant virus (rHVT) as an in ovo vaccine to protect specific-pathogen-free chickens against Newcastle disease (ND) and Marek's disease (MD). The rHVT, designed to express fusion (F) and hemagglutinin-neuraminidase (HN) glycoproteins of the lentogenic Hitchner B1 strain of ND virus (NDV), as well as glycoproteins A and B of the GA strain of serotype 1 MD virus (MDV) was efficacious in protecting chickens against ND and MD. No adverse effects on hatchability or the survival of chickens were observed following in ovo vaccination with rHVT. A single administration at embryonation day 18 (ED18) or at hatch protected chickens against challenge-exposures with virulent MDV strain RB-1B and velogenic NDV strain GB-Texas (NDV-GB-TX). Vaccinated chickens developed antibodies against both viruses as detected by serological tests, namely, hemagglutination inhibition, virus neutralization and western immunoblotting for NDV, and immunofluorescence and radioimmunoprecipitation assays for MDV. PCR analysis showed that in ovo vaccination with rHVT resulted in a persistent infection leading to systemic immunity against ND for up to 8 weeks of age, the longest period of time tested in this study. However, virus isolation tests indicated that rHVT-vaccinated chickens were only partially protected from the replication of NDV-GB-TX in the trachea. The results of the study indicate that rHVT is safe for both ED18 and posthatch vaccination for ND and MD, and because the vaccine persists, it may induce longer lasting immunity than conventional live NDV vaccines.

Original languageEnglish (US)
Pages (from-to)469-477
Number of pages9
JournalVaccine
Volume14
Issue number6
DOIs
StatePublished - Apr 1996
Externally publishedYes

Fingerprint

Meleagrid Herpesvirus 1
Newcastle Disease
Meleagrid herpesvirus 1
Marek Disease
Specific Pathogen-Free Organisms
Marek disease
Newcastle disease
Chickens
Vaccines
vaccines
chickens
Viruses
viruses
pathogens
vaccination
Vaccination
glycoproteins
Gallid Herpesvirus 2
Gallid herpesvirus 2
immunity

Keywords

  • Fusion and hemagglutinin genes
  • Glycoprotein A,B of Marek's disease virus
  • In ovo vaccination
  • Marek's disease
  • Newcastle disease
  • Recombinant herpesvirus of turkeys

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Protective efficacy of a recombinant herpesvirus of turkeys as an in ovo vaccine against Newcastle and Marek's diseases in specific-pathogen-free chickens. / Reddy, S. K.; Sharma, J. M.; Ahmad, J.; Reddy, D. N.; McMillen, J. K.; Cook, S. M.; Wild, M. A.; Schwartz, R. D.

In: Vaccine, Vol. 14, No. 6, 04.1996, p. 469-477.

Research output: Contribution to journalArticle

Reddy, S. K. ; Sharma, J. M. ; Ahmad, J. ; Reddy, D. N. ; McMillen, J. K. ; Cook, S. M. ; Wild, M. A. ; Schwartz, R. D. / Protective efficacy of a recombinant herpesvirus of turkeys as an in ovo vaccine against Newcastle and Marek's diseases in specific-pathogen-free chickens. In: Vaccine. 1996 ; Vol. 14, No. 6. pp. 469-477.
@article{bba1509ec64a4a2cb01bb670796a38f2,
title = "Protective efficacy of a recombinant herpesvirus of turkeys as an in ovo vaccine against Newcastle and Marek's diseases in specific-pathogen-free chickens",
abstract = "We investigated the potential of a herpesvirus of turkey (HVT)-based recombinant virus (rHVT) as an in ovo vaccine to protect specific-pathogen-free chickens against Newcastle disease (ND) and Marek's disease (MD). The rHVT, designed to express fusion (F) and hemagglutinin-neuraminidase (HN) glycoproteins of the lentogenic Hitchner B1 strain of ND virus (NDV), as well as glycoproteins A and B of the GA strain of serotype 1 MD virus (MDV) was efficacious in protecting chickens against ND and MD. No adverse effects on hatchability or the survival of chickens were observed following in ovo vaccination with rHVT. A single administration at embryonation day 18 (ED18) or at hatch protected chickens against challenge-exposures with virulent MDV strain RB-1B and velogenic NDV strain GB-Texas (NDV-GB-TX). Vaccinated chickens developed antibodies against both viruses as detected by serological tests, namely, hemagglutination inhibition, virus neutralization and western immunoblotting for NDV, and immunofluorescence and radioimmunoprecipitation assays for MDV. PCR analysis showed that in ovo vaccination with rHVT resulted in a persistent infection leading to systemic immunity against ND for up to 8 weeks of age, the longest period of time tested in this study. However, virus isolation tests indicated that rHVT-vaccinated chickens were only partially protected from the replication of NDV-GB-TX in the trachea. The results of the study indicate that rHVT is safe for both ED18 and posthatch vaccination for ND and MD, and because the vaccine persists, it may induce longer lasting immunity than conventional live NDV vaccines.",
keywords = "Fusion and hemagglutinin genes, Glycoprotein A,B of Marek's disease virus, In ovo vaccination, Marek's disease, Newcastle disease, Recombinant herpesvirus of turkeys",
author = "Reddy, {S. K.} and Sharma, {J. M.} and J. Ahmad and Reddy, {D. N.} and McMillen, {J. K.} and Cook, {S. M.} and Wild, {M. A.} and Schwartz, {R. D.}",
year = "1996",
month = "4",
doi = "10.1016/0264-410X(95)00242-S",
language = "English (US)",
volume = "14",
pages = "469--477",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Protective efficacy of a recombinant herpesvirus of turkeys as an in ovo vaccine against Newcastle and Marek's diseases in specific-pathogen-free chickens

AU - Reddy, S. K.

AU - Sharma, J. M.

AU - Ahmad, J.

AU - Reddy, D. N.

AU - McMillen, J. K.

AU - Cook, S. M.

AU - Wild, M. A.

AU - Schwartz, R. D.

PY - 1996/4

Y1 - 1996/4

N2 - We investigated the potential of a herpesvirus of turkey (HVT)-based recombinant virus (rHVT) as an in ovo vaccine to protect specific-pathogen-free chickens against Newcastle disease (ND) and Marek's disease (MD). The rHVT, designed to express fusion (F) and hemagglutinin-neuraminidase (HN) glycoproteins of the lentogenic Hitchner B1 strain of ND virus (NDV), as well as glycoproteins A and B of the GA strain of serotype 1 MD virus (MDV) was efficacious in protecting chickens against ND and MD. No adverse effects on hatchability or the survival of chickens were observed following in ovo vaccination with rHVT. A single administration at embryonation day 18 (ED18) or at hatch protected chickens against challenge-exposures with virulent MDV strain RB-1B and velogenic NDV strain GB-Texas (NDV-GB-TX). Vaccinated chickens developed antibodies against both viruses as detected by serological tests, namely, hemagglutination inhibition, virus neutralization and western immunoblotting for NDV, and immunofluorescence and radioimmunoprecipitation assays for MDV. PCR analysis showed that in ovo vaccination with rHVT resulted in a persistent infection leading to systemic immunity against ND for up to 8 weeks of age, the longest period of time tested in this study. However, virus isolation tests indicated that rHVT-vaccinated chickens were only partially protected from the replication of NDV-GB-TX in the trachea. The results of the study indicate that rHVT is safe for both ED18 and posthatch vaccination for ND and MD, and because the vaccine persists, it may induce longer lasting immunity than conventional live NDV vaccines.

AB - We investigated the potential of a herpesvirus of turkey (HVT)-based recombinant virus (rHVT) as an in ovo vaccine to protect specific-pathogen-free chickens against Newcastle disease (ND) and Marek's disease (MD). The rHVT, designed to express fusion (F) and hemagglutinin-neuraminidase (HN) glycoproteins of the lentogenic Hitchner B1 strain of ND virus (NDV), as well as glycoproteins A and B of the GA strain of serotype 1 MD virus (MDV) was efficacious in protecting chickens against ND and MD. No adverse effects on hatchability or the survival of chickens were observed following in ovo vaccination with rHVT. A single administration at embryonation day 18 (ED18) or at hatch protected chickens against challenge-exposures with virulent MDV strain RB-1B and velogenic NDV strain GB-Texas (NDV-GB-TX). Vaccinated chickens developed antibodies against both viruses as detected by serological tests, namely, hemagglutination inhibition, virus neutralization and western immunoblotting for NDV, and immunofluorescence and radioimmunoprecipitation assays for MDV. PCR analysis showed that in ovo vaccination with rHVT resulted in a persistent infection leading to systemic immunity against ND for up to 8 weeks of age, the longest period of time tested in this study. However, virus isolation tests indicated that rHVT-vaccinated chickens were only partially protected from the replication of NDV-GB-TX in the trachea. The results of the study indicate that rHVT is safe for both ED18 and posthatch vaccination for ND and MD, and because the vaccine persists, it may induce longer lasting immunity than conventional live NDV vaccines.

KW - Fusion and hemagglutinin genes

KW - Glycoprotein A,B of Marek's disease virus

KW - In ovo vaccination

KW - Marek's disease

KW - Newcastle disease

KW - Recombinant herpesvirus of turkeys

UR - http://www.scopus.com/inward/record.url?scp=0029931205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029931205&partnerID=8YFLogxK

U2 - 10.1016/0264-410X(95)00242-S

DO - 10.1016/0264-410X(95)00242-S

M3 - Article

VL - 14

SP - 469

EP - 477

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 6

ER -